Agenus Inc (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies, announced yesterday that it has named Dr Allison Jeynes-Ellis as its new director.
Jeynes-Ellis, MD, FFPM (UK) is a trained clinician with more than 25 years of senior leadership experience in the pharmaceutical industry. Presently, she serves as chief executive officer at Avillion LLP.
Previously, she led development at Wyeth, BMS, Novartis, and GSK and has secured numerous US and EU drug approvals.
Garo Armen, PhD, chairman and CEO of Agenus, said, 'As we advance towards becoming a commercial organisation, I am delighted to welcome Dr Jeynes-Ellis to our board. Allison brings significant global drug development and commercialisation experience, which includes executing on global registrational studies resulting in regulatory approvals in US and EU and advising on commercialisation and reimbursement strategies. We will benefit from Allison's considerable development, regulatory, and commercial expertise.'
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine